HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease

Files in This Item:
ClinNeuropharmacol40_261.pdf346.84 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/71786

Title: The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease
Other Titles: The efficacy of istradefylline for treating mild wearing-off in Parkinson's disease
Authors: Yabe, Ichiro Browse this author →KAKEN DB
Kitagawa, Mayumi Browse this author
Takahashi, Ikuko Browse this author
Matsushima, Masaaki Browse this author →ORCID
Sasaki, Hidenao Browse this author →KAKEN DB
Keywords: Parkinson's disease
istradefylline
wearing-off
Issue Date: Nov-2017
Publisher: Wolters Kluwer Health
Journal Title: Clinical Neuropharmacology
Volume: 40
Issue: 6
Start Page: 261
End Page: 263
Publisher DOI: 10.1097/WNF.0000000000000249
PMID: 28976411
Abstract: Objectives: The adenosine A2A antagonist istradefylline has been used to treat Parkinson disease (PD) with symptoms of wearing-off since 2013 in Japan. Previous randomized controlled trials of istradefylline compared with placebo included PD patients experiencing an average daily OFF time of more than 2 hours. The purpose of this study is to assess the efficacy of 20 mg/d istradefylline in PD subjects experiencing an average daily OFF time of 3 hours or less. Methods: Fifteen patients were enrolled into this retrospective study. They received 20 mg/d istradefylline for 12 weeks. Changes in the Unified Parkinson's Disease Rating Scale part III scores in the ON state (ON-UPDRS-III) scores and daily OFF time were assessed at baseline and after 4, 8, and 12 weeks of administration of istradefylline. Results: At baseline, all subjects had shorter daily OFF times, lower doses of L-DOPA and higher ON-UPDRS-III scores than those in previous randomized controlled trials. Twelve weeks of istradefylline significantly reduced ON-UPDRS-III scores (P < 0.001, Wilcoxon signed rank test). Eleven patients (73%) showed more than 50% reductions in ON-UPDRS-III scores. Improvement of ON-UPDRS-III was significantly correlated with baseline ON-UPDRS-III, and the mean ON-UPDRS-III score at end point was 12.1. Conclusions: Our result suggests that 20 mg/d istradefylline significantly improved motor functions in PD patients with mild wearing-off.
Rights: This is a non-final version of an article published in final form in Clinical Neuropharmacology, Volume 40, Issue 6, 2017, pp.261–263.
Type: article (author version)
URI: http://hdl.handle.net/2115/71786
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 矢部 一郎

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University